Clinical study of squamous cell carcinoma of maxillary sinus

Abstract

To evaluate the efficacy of multimodality therapy including radical surgery, radiation therapy, and chemotherapy for maxillary sinus cancer, we analyzed 59 patients in our institute between 2002 and 2019. We reviewed the 3-year overall survival rate to assess the efficacy of the therapy. The 3-year overall survival rate was 64.4％ for all patients, 100％ for patients in stage Ⅰ, 100％ in stage Ⅲ, 59.3％ in stage ⅣA, and 18.2％ in stage ⅣB. The 3-year overall survival rate was 90.0％ in the surgery with preoperative radiotherapy group, 74.1％ in the surgery with or without postoperative radiotherapy group, and 41.0％ in the radiotherapy or chemoradiotherapy group. Our results indicate the necessity of multimodal therapy for maxillary sinus cancer.